MedImmune has secured orphan drug designation from the the US Food and Drug Administration (FDA) for its MEDI-551 neuromyelitis optica drug.
MEDI-551 is an anti-CD19 monoclonal antibody indicated to treat neuromyelitis optica and neuromyelitis optica spectrum disorders.
{iframe}http://www.pharmaceutical-business-review.com/news/fda-grants-orphan-drug-status-to-medimmunes-medi-551-neuromyelitis-optica-drug-100315-4835037{/iframe}